Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?

Stryker Corporation (SYK) is poised to report strong Q2 2025 results, with consensus estimates projecting 9.9% revenue growth to $5.96 billion and 8.9% EPS growth to $3.06, primarily fueled by robust Mako robotic surgery utilization and successful new product introductions across its Orthopaedics and MedSurg segments. While the company anticipates full-year EPS of $13.20-$13.45, it faces a significant $200 million annual tariff headwind, largely impacting H2 2025, along with increased interest expenses from the Inari acquisition and lingering supply-chain issues. The Zacks model, however, does not conclusively predict an earnings beat for the upcoming Q2 report.

Analysis

Stryker Corporation is positioned for a strong second-quarter 2025 revenue report, with consensus estimates projecting a 9.9% increase to $5.96 billion and an 8.9% rise in EPS to $3.06. This growth is primarily fueled by robust underlying fundamentals, including strong procedural volumes and successful product launches. Key drivers include continued momentum from the Mako robotic-assisted surgery system, which achieved record installations in the prior quarter, and double-digit growth in capital-heavy businesses within the MedSurg and Neurotechnology segment. However, this positive top-line narrative is counterbalanced by significant emerging headwinds. The company has flagged a $200 million annual impact from newly imposed tariffs, which is expected to begin affecting results in Q2 and intensify through the second half of 2025. This, combined with higher interest expenses from the Inari acquisition and potential supply-chain drags, poses a risk to the margin expansion seen in Q1, where operating margin rose 100 basis points. While the company maintains full-year EPS guidance of $13.20-$13.45, the Zacks model's negative Earnings ESP of -0.17% suggests an earnings beat is not conclusive, indicating that strong sales could be tempered by these escalating cost pressures.

Key Decisions for Investors

• Investors should focus on management's commentary regarding the full-year guidance and the expected cadence of the $200 million tariff impact, as any downward revision or cautious tone on H2 profitability could overshadow strong Q2 revenue.
• Pay close attention to gross and operating margin figures in the Q2 report, as they will be the first quantitative indicator of Stryker's ability to offset new tariff and interest expenses through pricing and operational efficiencies.
• Given the conflicting signals of strong organic growth versus significant cost headwinds, it may be prudent to wait for the post-earnings management call for clarity on margin trajectory before initiating or adding to a position.